EMEA-001782-PIP01-15-M03
Key facts
| Invented name |
Influvac Tetra
|
| Active substance |
Influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains: A/(H1N1), A/(H3N2), B/Yamagata lineage, B/Victoria lineage
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/0211/2018
|
| PIP number |
EMEA-001782-PIP01-15-M03
|
| Pharmaceutical form(s) |
Suspension for injection
|
| Condition(s) / indication(s) |
Prevention of influenza infection
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
Abbott Biologicals B.V.
Tel. +41 6148 70374
Email: hind.ounis@abbott.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-001782-PIP01-15-M03
|
| Compliance opinion date |
04/09/2020
|
| Compliance outcome |
positive
|